Cited by 219Drug-Induced Adverse ReactionsFood Allergy and Anaphylaxis ResearchPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

Open access

Wang, Cunlin, Graham, David J., Kane, Robert C., Xie, Diqiong, Wernecke, Michael, Levenson, Mark, MaCurdy, Thomas E., Houstoun, Monica, Ryan, Qin, Wong, Sarah, Mott, Katrina, Sheu, Ting-Chang, Limb, Susan, Worrall, Chris, Kelman, Jeffrey A., Reichman, Marsha E.·2015·JAMA

DOI 10.1001/jama.2015.15572

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: All intravenous (IV) iron products are associated with anaphylaxis, but the comparative safety of each product has not been well established. OBJECTIVE: To compare the risk of anaphylaxis among marketed IV iron products. DESIGN, SETTING, AND PARTICIPANTS: Retrospective new user cohort study of IV iron recipients (n = 688,183) enrolled in the US fee-for-service Medicare program from January 2003 to December 2013. Analyses involving ferumoxytol were limited to the period January 2010 to December 2013. EXPOSURES: Administrations of IV iron dextran, gluconate, sucrose, or ferumoxytol as reported in outpatient Medicare claims data. MAIN OUTCOMES AND MEASURES: Anaphylaxis was identified using a prespecified and validated algorithm defined with standard diagnosis and procedure codes and applied to both inpatient and outpatient Medicare claims. The absolute and relative risks of anaphylaxis were estimated, adjusting for imbalances among treatment groups. RESULTS: A total of 274 anaphylaxis cases were identified at first exposure, with an additional 170 incident anaphylaxis cases identified during subsequent IV iron administrations. The risk for anaphylaxis at first exposure was 68 per 100,000 persons for iron dextran (95% CI, 57.8-78.7 per 100,000) and 24 per 100,000 persons for all nondextran IV iron products combined (iron sucrose, gluconate, and ferumoxytol) (95% CI, 20.0-29.5 per 100,000) , with an adjusted odds ratio (OR) of 2.6 (95% CI, 2.0-3.3; P < .001). At first exposure, when compared with iron sucrose, the adjusted OR of anaphylaxis for iron dextran was 3.6 (95% CI, 2.4-5.4); for iron gluconate, 2.0 (95% CI 1.2, 3.5); and for ferumoxytol, 2.2 (95% CI, 1.1-4.3). The estimated cumulative anaphylaxis risk following total iron repletion of 1000 mg administered within a 12-week period was highest with iron dextran (82 per 100,000 persons, 95% CI, 70.5- 93.1) and lowest with iron sucrose (21 per 100,000 persons, 95% CI, 15.3- 26.4). CONCLUSIONS AND RELEVANCE: Among patients in the US Medicare nondialysis population with first exposure to IV iron, the risk of anaphylaxis was highest for iron dextran and lowest for iron sucrose.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2015.15572

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Categorical Data Analysis
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Categorical Data Analysis
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N., Bock, S. A., Branum, A., Brown, S., Camargo, C. A., Cydulka, R., Galli, S., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,170
A systematic analysis of global anemia burden from 1990 to 2010
Kassebaum, N. J., Jasrasaria, R., Naghavi, M., Wulf, S. K., Johns, N. E., Lozano, R., Regan, M. C., Weatherall, D. J., Chou, D. P., Eisele, T. P., et al. (2013) · Blood · doi:10.1182/blood-2013-06-508325 · Cited by 2,115
Categorical Data Analysis
(2010) · Sage eBooks · doi:10.4135/9781412961288.n40 · Cited by 2,028
Untitled work
(1953) · Medical Entomology and Zoology · Cited by 1,321
Update on adverse drug events associated with parenteral iron
Chertow, G. M., Mason, P. D., Vaage-Nilsen, O., & Ahlmén, J. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi253 · Cited by 457
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
Auerbach, M., & Ballard, H. S. (2010) · Hematology · doi:10.1182/asheducation-2010.1.338 · Cited by 311
The safety of intravenous iron dextran in hemodialysis patients
Fishbane, S., Ungureanu, V.-D., Maesaka, J. K., Kaupke, C. J., LIM, V. S., & Wish, J. B. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90463-1 · Cited by 271

Show all 28 references

Sorted by citations

Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez‐Rodríguez, A., & Caravan, P. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,647
Nanomaterials for In Vivo Imaging
Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,084
Iron deficiency anaemia: pathophysiology, assessment, practical management
Kumar, A., Sharma, E., Marley, A., Samaan, M., & Brookes, M. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000759 · Cited by 351
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Batchelor, E. K., Kapitsinou, P. P., Pérgola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020213 · Cited by 349
Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis
Shepshelovich, D., Rozen‐Zvi, B., Avni, T., Gafter, U., & Gafter‐Gvili, A. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.04.018 · Cited by 322
Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
Hanna, R. M., Streja, E., & Kalantar‐Zadeh, K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01524-6 · Cited by 235
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., Małyszko, J., Swinkels, D. W., Tarng, D., Cheung, M., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.020 · Cited by 222
Iron deficiency and cardiovascular disease
Savarese, G., von Haehling, S., Butler, J., Cleland, J. G. F., Ponikowski, P. P., & Anker, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac569 · Cited by 203
Chronic kidney disease
Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez‐Iturbe, B., & Anders, H. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 237
Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI
Nguyen, K., Yoshida, T., Kathuria‐Prakash, N., Zaki, I. H., Várallyay, C. G., Semple, S. I. K., Saouaf, R., Rigsby, C. K., Stoumpos, S., Whitehead, K. K., et al. (2019) · Radiology · doi:10.1148/radiol.2019190477 · Cited by 169
The available intravenous iron formulations: History, efficacy, and toxicology
Auerbach, M., & Macdougall, I. C. (2017) · Hemodialysis International · doi:10.1111/hdi.12560 · Cited by 158
Single-dose intravenous iron for iron deficiency: a new paradigm
Auerbach, M., & Deloughery, T. (2016) · Hematology · doi:10.1182/asheducation-2016.1.57 · Cited by 148
Risk of Infection Associated With Administration of Intravenous Iron
Shah, A., Donovan, K., Seeley, C., Dickson, E. A., Palmer, A. J. R., Doree, C. J., Brunskill, S. J., Reid, J., Acheson, A. G., Sugavanam, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.33935 · Cited by 143
Current misconceptions in diagnosis and management of iron deficiency.
Múñoz, M., Gómez‐Ramírez, S., Besser, M. W., Pavı́a, J., Gomollón, F., Liumbruno, G. M., Bhandari, S., Cladellas, M., Shander, A., & Auerbach, M. (2017) · PubMed Central · doi:10.2450/2017.0113-17 · Cited by 149
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
Adkinson, N. F., Strauss, W., Macdougall, I. C., Bernard, K. E., Auerbach, M., Kaper, R. F., Chertow, G. M., & Krop, J. S. (2018) · American Journal of Hematology · doi:10.1002/ajh.25060 · Cited by 130
Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia
Iolascon, A., Andolfo, I., Russo, R., Sánchez, M., Busti, F., Swinkels, D. W., Aguilar‐Martinez, P., Bou‐Fakhredin, R., Muckenthaler, M. U., Ünal, Ş., et al. (2024) · HemaSphere · doi:10.1002/hem3.108 · Cited by 177
Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice
McDonagh, T., Damy, T., Doehner, W., Lam, C. S. P., Sindone, A., van der Meer, P., Cohen-Solal, A., Kindermann, I., Manito, N., Pfister, O., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1305 · Cited by 121
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia
Fishbane, S. N., Block, G. A., Loram, L. C., Neylan, J. F., Pérgola, P. E., Uhlig, K., & Chertow, G. M. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101053 · Cited by 120
Iron supplementation and iron-fortified foods: a review
Man, Y., Xu, T., Adhikari, B., Zhou, C., Wang, Y., & Wang, B. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1876623 · Cited by 139
Iron deficiency anemia in pregnancy
James, A. H. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004559 · Cited by 112
A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
Auerbach, M., Henry, D. H., Derman, R. J., Achebe, M. M., Thomsen, L. L., & Glaspy, J. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25564 · Cited by 107
Intravenous iron supplementation therapy
Schaefer, B., Meindl, E., Wagner, S., Tilg, H., & Zoller, H. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100862 · Cited by 102
Quercetin attenuates neurotoxicity induced by iron oxide nanoparticles
Bardestani, A., Ebrahimpour, S., Esmaeili, A., & Esmaeili, A. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01059-0 · Cited by 106
Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion
Surbek, D., Vial, Y., Girard, T., Breymann, C., Bencaiova, G. A., Baud, D., Hornung, R., Taleghani, B. M., & Hösli, I. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05374-8 · Cited by 99
Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review
Glaspy, J. A., Lim-Watson, M. Z., Libre, M., Karkare, S., Hadker, N., Bajic-Lucas, A., Strauss, W., & Dahl, N. V. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s243462 · Cited by 92
Intravenous Irons: From Basic Science to Clinical Practice
Bhandari, S., Pereira, D. I. A., Chappell, H. F., & Drakesmith, H. (2018) · Pharmaceuticals · doi:10.3390/ph11030082 · Cited by 88
Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
Arastu, A., Elstrott, B. K., Martens, K. L., Cohen, J., Oakes, M. H., Rub, Z. T., Aslan, J. E., DeLoughery, T. G., & Shatzel, J. J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.4488 · Cited by 82
The safety of available treatment options for iron-deficiency anemia
Múñoz, M., Gómez‐Ramírez, S., & Bhandari, S. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1400009 · Cited by 78
Prediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
Safety concerns about intravenous iron therapy in patients with chronic kidney disease
Vecchio, L. D., Longhi, S., & Locatelli, F. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfv142 · Cited by 70
Preoperative anemia-screening clinics
Lin, Y. (2019) · Hematology · doi:10.1182/hematology.2019000061 · Cited by 68
Distinct in vitro Complement Activation by Various Intravenous Iron Preparations
Hempel, J. C., Poppelaars, F., da Costa, M. G., Franssen, C. F. M., De Vlaam, T. P. G., Daha, M. R., Berger, S. P., Seelen, M. A., & Gaillard, S. (2016) · American Journal of Nephrology · doi:10.1159/000451060 · Cited by 67
Management and prevention of anemia (acute bleeding excluded) in adult critical care patients
Lasocki, S., Pène, F., Ait‐Oufella, H., Aubron, C., Ausset, S., Buffet, P. A., Huet, O., Launey, Y., Legrand, M. M., Lescot, T., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00711-6 · Cited by 68
Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice
Richards, T., Breymann, C., Brookes, M., Lindgren, S. C., Macdougall, I. C., McMahon, L. P., Munro, M. G., Nemeth, E., Rosano, G. M. C., Schiefke, I., et al. (2021) · Annals of Medicine · doi:10.1080/07853890.2020.1867323 · Cited by 64
PEGylation technology: addressing concerns, moving forward
Simberg, D., Barenholz, Y., Roffler, S. R., Landfester, K., Kabanov, A. V., & Moghimi, S. M. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2494775 · Cited by 65
Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults
Lim, W., Afif, W., Knowles, S. R., Lim, G., Lin, Y., Mothersill, C., Nistor, I. M., Rehman, F., Song, C., & Xenodemetropoulos, T. (2019) · Vox Sanguinis · doi:10.1111/vox.12773 · Cited by 57
Intravenous or oral iron for treating iron deficiency anaemia during pregnancy: systematic review and meta‐analysis
Qassim, A., Grivell, R. M., Henry, A., Kidson‐Gerber, G., Shand, A., & Grzeskowiak, L. E. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50308 · Cited by 58
Iron metabolism and management: focus on chronic kidney disease
Agarwal, A. K. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.003 · Cited by 57
Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry
Yuan, H., Wilks, M. Q., Normandin, M. D., Fakhri, G. E., Kaittanis, C., & Josephson, L. (2018) · Nature Protocols · doi:10.1038/nprot.2017.133 · Cited by 52
MRI with ferumoxytol: A single center experience of safety across the age spectrum
Nguyen, K., Yoshida, T., Han, F., Ayad, I., Reemtsen, B. L., Salusky, I. B., Satou, G. M., Hu, P., & Finn, J. P. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25412 · Cited by 51
Safety of intravenous iron use in chronic kidney disease
Kalra, P. A., & Bhandari, S. (2016) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000263 · Cited by 50
Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial
Vanobberghen, F. M., Lweno, O., Kuemmerle, A., Mwebi, D. K., Asilia, P. J., Issa, A., Simon, B., Mswata, S., Schmidlin, S., Glass, T. R., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30448-4 · Cited by 50
A Nanomedicine Structure–Activity Framework for Research, Development, and Regulation of Future Cancer Therapies
Youden, B., Jiang, R., Carrier, A. J., Servos, M. R., & Zhang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c06337 · Cited by 53
Iron deficiency anemia in pregnancy
Igbinosa, I. I., Berube, C., & Lyell, D. J. (2022) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000772 · Cited by 48
Risks for Anaphylaxis With Intravenous Iron Formulations
Dave, C. V., Brittenham, G. M., Carson, J. L., & Setoguchi, S. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4009 · Cited by 49
Dextran-Mimetic Quantum Dots for Multimodal Macrophage Imaging In Vivo, Ex Vivo, and In Situ
Deng, H., Konopka, C. J., Prabhu, S., Sarkar, S., Medina, N. G., Fayyaz, M., Arogundade, O. H., Gamage, H. E. V., Shahoei, S. H., Nall, D., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c07010 · Cited by 47
Cornerstones of patient blood management in surgery
Butcher, A., & Richards, T. (2017) · Transfusion Medicine · doi:10.1111/tme.12476 · Cited by 46
Current evaluation and management of anemia in patients with inflammatory bowel disease
Martin, J., Radeke, H. H., Dignass, A. U., & Stein, J. M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1263566 · Cited by 47
Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures
Nathell, L., Gohlke, A., & Wohlfeil, S. (2019) · Drug Safety · doi:10.1007/s40264-019-00868-5 · Cited by 43
Hypersensitivity reactions in patients receiving hemodialysis
Butani, L., & Calogiuri, G. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.04.006 · Cited by 41
Pathogenesis, diagnosis and treatment of anaemia in immune‐mediated gastrointestinal disorders
Bergamaschi, G., Sabatino, A. D., & Corazza, G. R. (2018) · British Journal of Haematology · doi:10.1111/bjh.15254 · Cited by 40
Differences Between Intravenous Iron Products: Focus on Treatment of Iron Deficiency in Chronic Heart Failure Patients
Martín‐Malo, A., Borchard, G., Flühmann, B., Mori, C., Silverberg, D. S., & Jankowska, E. A. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12400 · Cited by 39
Iron deficiency anemia in the emergency department: over-utilization of red blood cell transfusion and infrequent use of iron supplementation
Spradbrow, J., Lin, Y., Shelton, D., & Callum, J. L. (2016) · Canadian Journal of Emergency Medicine · doi:10.1017/cem.2016.388 · Cited by 35
Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
EHLKEN, B., Nathell, L., Gohlke, A., Bocuk, D., Toussi, M., & Wohlfeil, S. (2018) · Drug Safety · doi:10.1007/s40264-018-0769-5 · Cited by 35
Perioperative Anemia Management
Abeysiri, S., Chau, M., & Richards, T. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1697933 · Cited by 55
Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice
Stein, J. M., Aksan, A., Farrag, K., Dignass, A. U., & Radeke, H. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1391790 · Cited by 33
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
Macdougall, I. C., Colet, J. C., Breymann, C., Spahn, D. R., & Κoutroubakis, I. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01323-z · Cited by 41
Utilization trends and safety of intravenous iron replacement in pediatric specialty care: A large retrospective cohort study
Boucher, A. A., Pfeiffer, A., Bedel, A., Young, J., & McGann, P. T. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.26995 · Cited by 33
Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
Trumbo, H., Kaluza, K., Numan, S., & Goodnough, L. T. (2020) · Drug Safety · doi:10.1007/s40264-020-01022-2 · Cited by 32
Iron Deficiency in CKD Without Concomitant Anemia
Wish, J. B., Anker, S. D., Butler, J., Cases, A., Stack, A. G., & Macdougall, I. C. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.07.032 · Cited by 34
Improving the safety of intravenous iron treatments for patients with chronic kidney disease
Kassianides, X., Hazara, A. M., & Bhandari, S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1853098 · Cited by 32
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiß, S., Yin, H., Franklin, J. M., Pawar, A. M., Santella, C., Yu, O. H. Y., Renoux, C., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac021 · Cited by 30
IV iron formulations and use in adults
Doren, L. V., & Auerbach, M. (2023) · Hematology · doi:10.1182/hematology.2023000495 · Cited by 29
Drug Allergy in Women
Lee, E. Y., Copaescu, A. M., Trubiano, J. A., Phillips, E. J., Wolfson, A. R., & Ramsey, A. C. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.09.031 · Cited by 28
Improving quality of care for patients with iron deficiency anemia presenting to the emergency department
Khadadah, F. M., Callum, J. L., Shelton, D., & Lin, Y. (2018) · Transfusion · doi:10.1111/trf.14626 · Cited by 29
Intravenous versus Oral Iron for Iron-Deficiency anemia in Pregnancy (IVIDA): A randomized controlled trial
Lewkowitz, A. K., Stout, M. J., Cooke, E., Deoni, S. C., D'Sa, V., Rouse, D. J., Carter, E. B., & Tuuli, M. G. (2022) · American Journal of Perinatology · doi:10.1055/s-0041-1740003 · Cited by 27
Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
Gargallo-Puyuelo, C. J., Alfambra, E., García‐Erce, J. A., & Gomollón, F. (2018) · Nutrients · doi:10.3390/nu10121959 · Cited by 27
Use of Radiocontrast Agents in CKD and ESRD
Bahrainwala, J. Z., Leonberg‐Yoo, A. K., & Rudnick, M. R. (2017) · Seminars in Dialysis · doi:10.1111/sdi.12593 · Cited by 25
Reports to FDA of fatal anaphylaxis associated with intravenous iron products
McCulley, L. V., Gelperin, K., Bird, S. T., Harris, S., Wang, C., & Waldron, P. E. (2016) · American Journal of Hematology · doi:10.1002/ajh.24531 · Cited by 25
Self-citation
Intravenous iron use in pregnancy: Ironing out the issues and evidence
Seeho, S. K. M., & Morris, J. M. (2018) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12794 · Cited by 25
Intravenous iron: do we adequately understand the short‐ and long‐term risks in clinical practice?
Rund, D. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.17202 · Cited by 25
Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation
Verhoef, J. J. F., de Groot, A. M., van Moorsel, M. V. A., Ritsema, J. A. S., Beztsinna, N., Maas, C., & Schellekens, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.025 · Cited by 24
Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
Lichtenstein, G. R., & Onken, J. E. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5204-3 · Cited by 24
Iron Deficiency in Women’s Health: New Insights into Diagnosis and Treatment
Moisidis-Tesch, C. M., & SHULMAN, L. P. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02157-7 · Cited by 29
Nanomaterials for antigen-specific immune tolerance therapy
Park, J.-W., Wu, Y., Li, Q., Choi, J., Ju, H., Cai, Y., Lee, J., & Oh, Y. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01233-3 · Cited by 25
Is low‐molecular weight iron dextran really the most risky iron?—Unconvincing data from an unconvincing study
DeLoughery, T. G., & Auerbach, M. (2016) · American Journal of Hematology · doi:10.1002/ajh.24326 · Cited by 22
Iron Treatment Strategies in Dialysis-Dependent CKD
Pandey, R., Daloul, R., & Coyne, D. W. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.02.004 · Cited by 22
Iron deficiency anaemia in pregnancy: The role of parenteral iron
Esen, U. I. (2016) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2016.1180505 · Cited by 23
Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA)
Neiser, S., Koskenkorva, T., Schwarz, K., Wilhelm, M., & Burckhardt, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071185 · Cited by 21
Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents
Ozsahin, H., Schaeppi, M., Bernimoulin, M. P., Allard, M., Guidard, C., & van den Ouweland, F. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28614 · Cited by 21
Recognizing who is at risk for postpartum hemorrhage: targeting anemic women and scoring systems for clinical use
Faysal, H., Araji, T., & Ahmadzia, H. K. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100745 · Cited by 20
The safety and efficacy of ferumoxytol in the treatment of iron deficiency: a systematic review and meta‐analysis
Abdulrehman, J., Tang, G. H., Auerbach, M., Santesso, N. A., & Sholzberg, M. (2019) · Transfusion · doi:10.1111/trf.15587 · Cited by 21
Management and prevention of anemia (acute bleeding excluded) in adult critical care patients
Lasocki, S., Pène, F., Ait‐Oufella, H., Aubron, C., Ausset, S., Buffet, P. A., Huet, O., Launey, Y., Legrand, M. M., Lescot, T., et al. (2020) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2020.04.004 · Cited by 22
Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010–2014
Akhuemonkhan, E., Parian, A. M., Carson, K. A., & Hutfless, S. M. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy063 · Cited by 19
Safety of Intravenous Iron – Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients
Sivakumar, C., Jubb, V. M., Lamplugh, A., & Bhandari, S. (2019) · Peritoneal Dialysis International · doi:10.3747/pdi.2018.00125 · Cited by 18
A retrospective study of the safety and efficacy of low molecular weight iron dextran for children with iron deficiency anemia
Boucher, A. A., Bedel, A., Jones, S., Lenahan, S. F., Geer, R., & McGann, P. T. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29024 · Cited by 18
Safety of intravenous iron in hemodialysis patients
Li, X., Kshirsagar, A. V., & Brookhart, M. A. (2017) · Hemodialysis International · doi:10.1111/hdi.12558 · Cited by 18
The patient with anemia
Shander, A., & Javidroozi, M. (2016) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000340 · Cited by 17
Approach to hypersensitivity reactions from intravenous iron preparations
Mateluna, C. M., Scherer, K., & Bircher, A. J. (2016) · Allergy · doi:10.1111/all.13106 · Cited by 17
Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study
Wetmore, J. B., Weinhandl, E. D., Zhou, J., & Gilbertson, D. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171098 · Cited by 17
New horizons in iron deficiency anaemia in older adults
Burton, J. K., Yates, L. C., Whyte, L., Fitzsimons, E. J., & Stott, D. J. (2020) · Age and Ageing · doi:10.1093/ageing/afz199 · Cited by 17
Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department
Motta, I., Mantovan, G., Consonni, D., Brambilla, A. M., Materia, M., Porzio, M., Amicis, M. M. D., Montano, N., & Cappellini, M. D. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02223-z · Cited by 16
Chronic Kidney Disease and End Stage Renal Disease
Martinusen, D. J., Marin, J., Cheng, E., & Lau, W. (2020) · Advanced clinical pharmacy - research, development and practical applications/Advanced clinical pharmacy - research, development and practical applications · doi:10.1007/978-3-030-37655-0_4 · Cited by 17
Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017
Durup, D., de Muckadell, P. S., & Strom, C. C. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1738215 · Cited by 15
Physicochemical characterization of ferric pyrophosphate citrate
Gupta, A., Pratt, R. D., & Mishra, B. (2018) · BioMetals · doi:10.1007/s10534-018-0151-1 · Cited by 14
Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol
Khan, H., May, P., Kuo, E., Pai, P., Boles, K., McGee, A., Dang, T., & Schmit, J. M. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211006022 · Cited by 14
Innovative Perspective: Gadolinium-Free Magnetic Resonance Imaging in Long-Term Follow-Up after Kidney Transplantation
van Eijs, M. J. M., van Zuilen, A. D., de Boer, A., Froeling, M., Nguyen, T. Q., Joles, J. A., Leiner, T., & Verhaar, M. C. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00296 · Cited by 14
High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial
Macher, S., Drexler, C., Lindenau, I., Sareban, N., Schlenke, P., & Amrein, K. (2016) · Trials · doi:10.1186/s13063-016-1648-y · Cited by 13
Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients
Kshirsagar, A. V., & Li, X. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.05.001 · Cited by 13
Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
Adkinson, F., Strauss, W., Bernard, K. E., Kaper, R. F., Macdougall, I. C., & Krop, J. S. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s142236 · Cited by 12

Authors: Wang, C., Graham, D. J., Kane, R. C., Xie, D., Wernecke, M., Levenson, M., MaCurdy, T. E., Houstoun, M., Ryan, Q., Wong, S., Mott, K., Sheu, T.-C., Limb, S., Worrall, C., Kelman, J. A., & Reichman, M. E.
Affiliations: United States Food and Drug Administration (US)
Acumen (United States) (US)
Centers for Medicare and Medicaid Services (US)
Corresponding author: Wang, Cunlin
ORCID: Graham, David J.
Wernecke, Michael
Levenson, Mark
MaCurdy, Thomas E.
Mott, Katrina
Sheu, Ting-Chang
Reichman, Marsha E.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2015-11-17
Volume: 314
Issue: 19
Pages: 2062
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2015.15572
OpenAlex: W2179358297
Cited by: 219
References: 28
Citations by year: 2026: 10 · 2025: 13 · 2024: 14 · 2023: 14 · 2022: 32 · 2021: 20 · 2020: 27 · 2019: 21 · 2018: 20 · 2017: 20 · 2016: 27 · 2015: 1
FWCI: 16.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: anaphylaxis, intravenous iron, iron dextran, iron sucrose, iron gluconate, ferumoxytol, drug safety, adverse drug reactions, iron deficiency anemia, Medicare beneficiaries, iron repletion
MeSH terms: Ferric Oxide, Saccharated, Aged, Anaphylaxis, Female, Ferric Compounds, Glucaric Acid, Gluconates, Humans, Injections, Intravenous, Iron-Dextran Complex, Male, Retrospective Studies, Risk, United States, Incidence, Medicare Part A, Ferrosoferric Oxide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks